Coherus BioSciences (CHRS)
(Delayed Data from NSDQ)
$1.39 USD
+0.07 (5.30%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $1.38 -0.01 (-0.72%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Price, Consensus and EPS Surprise
CHRS 1.39 +0.07(5.30%)
Will CHRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for CHRS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CHRS
Coherus BioSciences (CHRS) Reports Q2 Loss, Tops Revenue Estimates
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
CHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Editas Medicine (EDIT) Reports Q1 Loss, Misses Revenue Estimates
Inovio Pharma (INO) Stock Rallies 134% in a Month: Here's Why
Coherus (CHRS) Stock Rallies on FDA Nod for Udenyca Onbody
Other News for CHRS
Barclays Keeps Their Buy Rating on Coherus Biosciences (CHRS)
Coherus Biosciences just downgraded at UBS, here's why
Coherus Biosciences: Hold Rating with Downward Revenue Projections and Price Target Revision
UBS cuts Coherus to neutral, cites limited growth opportunities
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects